Christopher Ma, MD, of University of Calgary, Alberta, Canada, discusses the results of the phase 1b/2 RESOLVE trial, evaluating EP-104GI, an injectable formulation of the steroid fluticasone, for treatment of eosinophilic esophagitis (EoE). In this trial, investigators found that EP-104GI had a stable and low-dose systemic exposure that was safe over time and that it led to improvement to a number of histologic parameters.
Dr. Ma concluded that these results show “proof of concept that this is a feasible procedure for patients, proof of concept that this mechanism of delivery can be potentially effective in eosinophilic esophagitis.”
Dr. Ma first presented these data at Digestive Disease Week 2026 in Chicago, Illinois.
Transcript:
This transcript has been edited for clarity.
Christopher Ma, MD: My name’s Chris Ma. I’m a gastroenterologist and associate professor in the Department of Medicine at the University of Calgary.
Gastro Today: What is the background information for this trial?
Dr. Ma: This is a phase 1b/2 study called RESOLVE. It looks at a novel compound called EP-104GI, which is an injectable fluticasone therapy for patients with eosinophilic esophagitis. The premise of the therapy is really to use a known mechanism of action in EoE, which is topical corticosteroids. It’s an important therapy. It’s a recommended therapy across different guidelines for EoE because it addresses multiple avenues of inflammation and the pathophysiology of the disease in a topical and controlled way.
Although swallowed topical corticosteroids are really the benchmark therapy in EoE, they’re limited by adherence over the long term. EP-104GI really tries to target that same mechanism but engineer a more elegant solution. It’s a long-acting fluticasone therapy. It’s injected and administered once and then provides long-term control at a local level with minimal systemic absorption.
The RESOLVE study was looking at EP-104GI in multiple ascending doses across 10 different cohorts. What we presented here was both pharmacokinetic safety and some histologic efficacy data with respect to this compound.
Gastro Today: What were the results from this study?
Dr. Ma: There were a number of really important findings. With respect to pharmacokinetics, it showed very stable and very-low-dose systemic exposure, which is important for a corticosteroid therapy. We showed that that was safe over time, with no significant changes in either cortisol levels or serum glucose, and there was no dose-limiting toxicity across the study that would be potentially related to steroid effects. That’s really important when thinking about a long-term treatment.
Then when we looked at the histology, there were histologic changes across a number of important parameters. We looked at the EoEHSS [EoE Histology Scoring System], which is an eight-item tool that measures both grade and stage of disease for both eosinophil and non-eosinophil–related histologic parameters, and showed reductions across the cohorts in the EoEHSS, both for inflammatory features and for architectural features.
Then we also looked at the peak eosinophil count, which showed reductions across the dosing cohorts for the peak eosinophil count.
Gastro Today: What are the next steps for this research?
Dr. Ma: This is obviously an early-phase trial, but it’s proof of concept that this is a feasible procedure for patients, proof of concept that this mechanism of delivery can be potentially effective in eosinophilic esophagitis.
This is being carried into a larger phase 2 study where the top two doses that were explored in the first phase of REVOLVE will be further interrogated. The goal is to show overall that this can be effective across a number of different disease activity measures in EoE and to evaluate across a larger population the efficacy and safety.